Claims
- 1. A pharmaceutical composition for the treatment of allergic reactions or inflammatory conditions associated with leukotriene D.sub.4 comprising a compound of the formula
- wherein Z is:
- (a) --(CH.sub.2).sub.n --; or
- (b) --(CH.sub.2).sub.p --CH=CH--(CH.sub.2).sub.q --;
- wherein m is an integer of from 2 to 6 inclusive;
- wherein n is an integer of from 1 to 3 inclusive;
- wherein p is an integer of from zero to 4 inclusive;
- wherein q is an integer of from zero to 4 inclusive;
- wherein p+q is equal to or less than 6;
- wherein R.sub.1, R.sub.2 and R.sub.6 are:
- (a) alkyl of 1 to 6 carbon atoms, inclusive, each being the same or different;
- wherein R.sub.3 is
- (a) hydrogen; or
- (b) alkyl of 1 to 6 carbon atoms, inclusive;
- wherein R.sub.4 is:
- (a) --CO.sub.2 H;
- (b) --CO.sub.2 R.sub.6 ;
- (c) --CONR.sub.7 R.sub.8 ; and
- wherein R.sub.7 and R.sub.8 are:
- (a) hydrogen;
- (b) alkyl of 1 to 6 carbon atoms, inclusive R.sub.7 and R.sub.8 each being the same or different; or
- (c) taken together with the nitrogen atom to which they are attached form a 5 or 6 member saturated N-heterocycle optionally substituted by carboxylic acid or methyl ester thereof with the balance of the members being carbon;
- or the pharmacologically acceptable addition salts thereof; and a pharmaceutically acceptable carrier.
- 2. A pharmaceutical composition according to claim 1 wherein R.sub.3 is alkyl.
- 3. A pharmaceutical composition according to claim 2 wherein said compound is methyl 3-[7-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propoxyl]-3,4-dihydro-2-methyl-8-propyl-2H-1-benzopyran-2-yl]propanoate.
- 4. A pharmaceutical composition according to claim 2 wherein said compound is 3-[7-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]-3,4-dihydro-2-methyl-8-propyl-2H-1-benzopyran-2-yl]propanoic acid.
- 5. A pharmaceutical composition according to claim 1 wherein R.sub.3 is --H.
- 6. A pharmaceutical composition according to claim 5 wherein said compound is ethyl 3-[7-[3-(4-acetyl-3-hydroxy-2-propylphenoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-yl]propanoate.
- 7. A pharmaceutical composition according to claim 5 wherein said compound is 3-[7-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-yl]propanoic acid.
- 8. A pharmaceutical composition for the treatment of allergic reactions or inflammatory conditions associated with leukotriene D.sub.4 comprising a compound of the formula ##STR80## wherein Z is: (a) --(CH.sub.2).sub.n --; or
- (b) --(CH.sub.2).sub.p --CH=CH--(CH.sub.2).sub.q --;
- wherein m is an integer of from 2 to 6 inclusive;
- wherein n is an integer of from 1 to 3 inclusive;
- wherein p is an integer of from zero to 4 inclusive;
- wherein q is an integer of from zero to 4 inclusive;
- wherein p+q is equal to or less than 6;
- wherein R.sub.1, R.sub.2 and R.sub.6 are:
- (a) alkyl of 1 to 6 carbon atoms, inclusive, each being the same or different;
- wherein R.sub.3 is
- (a) hydrogen; or
- (b) alkyl of 1 to 6 carbon atoms, inclusive;
- wherein R.sub.4 is:
- (a) --CO.sub.2 H;
- (b) --CO.sub.2 R.sub.6 ;
- (c) --CONR.sub.7 R.sub.8 ; and
- wherein R.sub.7 and R.sub.8 are:
- (a) hydrogen;
- (b) alkyl of 1 to 6 carbon atoms, inclusive, R.sub.7 and R.sub.8 each being the same or different; or the pharmacologically acceptable addition salts thereof; and a pharmaceutically acceptable carrier.
- 9. A method of treating allergic reactions associated with leukotriene D.sub.4 in a mammal comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 1 to a mammal in need of such treatment.
- 10. A method of treating allergic reactions associated with leukotriene D.sub.4 in a mammal comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 2 to a mammal in need of such treatment.
- 11. A method of treating allergic reactions associated with leukotriene D.sub.4 in a mammal comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 3 to a mammal in need of such treatment.
- 12. A method of treating allergic reactions associated with leukotriene D.sub.4 in a mammal comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 4 to a mammal in need of such treatment.
- 13. A method of treating allergic reactions associated with leukotriene D.sub.4 in a mammal comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 5 to a mammal in need of such treatment.
- 14. A method of treating allergic reactions associated with leukotriene D.sub.4 in a mammal comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 6 to a mammal in need of such treatment.
- 15. A method of treating allergic reactions associated with leukotriene D.sub.4 in a mammal comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 7 to a mammal in need of such treatment.
- 16. A method of treating allergic reactions associated with leukotriene D.sub.4 in a mammal comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 8 to a mammal in need of such treatment.
- 17. A method of treating inflammatory conditions associated with leukotriene D.sub.4 in a mammal comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 1 to a mammal in need of such treatment.
- 18. A method of treating inflammatory conditions associated with leukotriene D.sub.4 in a mammal comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 2 to a mammal in need of such treatment.
- 19. A method of treating inflammatory conditions associated with leukotriene D.sub.4 in a mammal comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 3 to a mammal in need of such treatment.
- 20. A method of treating inflammatory conditions associated with leukotriene D.sub.4 in a mammal comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 4 to a mammal in need of such treatment.
- 21. A method of treating inflammatory conditions associated with leukotriene D.sub.4 in a mammal comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 5 to a mammal in need of such treatment.
- 22. A method of treating inflammatory conditions associated with leukotriene D.sub.4 in a mammal comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 6 to a mammal in need of such treatment.
- 23. A method of treating inflammatory conditions associated with leukotriene D.sub.4 in a mammal comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 7 to a mammal in need of such treatment.
- 24. A method of treating inflammatory conditions associated with leukotriene D.sub.4 in a mammal comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 8 to a mammal in need of such treatment.
Parent Case Info
This is a continuation of application Ser. No. 0/681,038 filed Dec. 12, 1984, l now U.S. Pat. No. 4,778,903, which is a divisional application of prior co-pending application Ser. No. 560,355, filed Dec. 12, 1983, now abandoned, which in turn is a continuation-in-part of application Ser. No. 520,973 filed Aug. 8, 1983, now abandoned.
US Referenced Citations (8)
Foreign Referenced Citations (3)
Number |
Date |
Country |
79637 |
May 1983 |
EPX |
1291864 |
Oct 1972 |
GBX |
1291865 |
Oct 1972 |
GBX |
Divisions (1)
|
Number |
Date |
Country |
Parent |
560355 |
Dec 1983 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
681038 |
Dec 1984 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
520973 |
Aug 1983 |
|